PBLD

Summary

PBLD (phenazine biosynthesis like protein domain containing, HGNC:23301) is a protein-coding gene on chromosome 10q21.3, encoding Phenazine biosynthesis-like domain-containing protein (P30039). Functions as a positive regulator of the antiviral immune response by modulating innate immunity and viral replication by enhancing type I interferon (IFN-I) response.

Enables identical protein binding activity. Involved in maintenance of gastrointestinal epithelium. Acts upstream of or within with a positive effect on negative regulation of transforming growth factor beta receptor signaling pathway. Located in cytoplasm.

Source: NCBI Gene 64081 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_022129

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23301
Approved symbol	PBLD
Name	phenazine biosynthesis like protein domain containing
Location	10q21.3
Locus type	gene with protein product
Status	Approved
Aliases	MAWBP, MAWDBP, FLJ14767
Ensembl gene	ENSG00000108187
Ensembl biotype	protein_coding
OMIM	612189
Entrez	64081

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 19 protein_coding, 2 retained_intron

ENST00000277795, ENST00000309049, ENST00000336578, ENST00000358769, ENST00000468798, ENST00000478192, ENST00000495025, ENST00000880158, ENST00000880159, ENST00000880160, ENST00000880161, ENST00000880162, ENST00000880163, ENST00000880164, ENST00000880165, ENST00000880166, ENST00000880167, ENST00000880168, ENST00000880169, ENST00000940606, ENST00000966864

RefSeq mRNA: 2 — MANE Select: NM_022129 NM_001033083, NM_022129

CCDS: CCDS44413, CCDS7277

Canonical transcript exons

ENST00000358769 — 10 exons

Exon	Start	End
ENSE00001461198	68332784	68332928
ENSE00003384900	68306761	68306903
ENSE00003707573	68296886	68296985
ENSE00003709756	68292129	68292238
ENSE00003711230	68292010	68292039
ENSE00003889779	68296266	68296364
ENSE00003891858	68285348	68285410
ENSE00003892115	68288483	68288661
ENSE00003895778	68282660	68284289
ENSE00003896100	68288931	68289019

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 99.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.3167 / max 472.1352, expressed in 1647 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
109749	3.6052	1560
109745	1.2518	43
109748	1.0298	621
109744	0.2801	24
109746	0.1185	28
109747	0.0313	15

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nephron tubule	UBERON:0001231	99.73	gold quality
jejunal mucosa	UBERON:0000399	99.61	gold quality
kidney epithelium	UBERON:0004819	99.53	gold quality
renal glomerulus	UBERON:0000074	99.39	gold quality
metanephric glomerulus	UBERON:0004736	99.31	gold quality
duodenum	UBERON:0002114	98.67	gold quality
renal medulla	UBERON:0000362	98.10	gold quality
liver	UBERON:0002107	97.97	gold quality
right lobe of liver	UBERON:0001114	97.72	gold quality
adult organism	UBERON:0007023	97.02	gold quality
adult mammalian kidney	UBERON:0000082	96.48	gold quality
ileal mucosa	UBERON:0000331	96.23	gold quality
kidney	UBERON:0002113	96.09	gold quality
colonic mucosa	UBERON:0000317	95.66	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.79	gold quality
cortex of kidney	UBERON:0001225	94.64	gold quality
endothelial cell	CL:0000115	94.33	gold quality
metanephros	UBERON:0000081	93.81	gold quality
body of pancreas	UBERON:0001150	93.71	gold quality
caput epididymis	UBERON:0004358	93.28	gold quality
mucosa of transverse colon	UBERON:0004991	92.89	gold quality
pylorus	UBERON:0001166	91.83	gold quality
rectum	UBERON:0001052	91.51	gold quality
small intestine	UBERON:0002108	91.11	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.20	gold quality
pancreas	UBERON:0001264	89.49	gold quality
cardia of stomach	UBERON:0001162	89.36	gold quality
bronchial epithelial cell	CL:0002328	89.07	gold quality
pancreatic ductal cell	CL:0002079	89.02	gold quality
body of stomach	UBERON:0001161	88.98	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	30.32
E-CURD-135	no	848.93
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

80 targeting PBLD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-93-5P	99.88	73.98	2606

Literature-anchored findings (GeneRIF, showing 6)

• Coexpression of MAWBP and MAWD inhibited epithelial mesenchymal transformation, and EMT-aided malignant cell progression was suppressed in gastric cancer. (PMID:23687415)
• MAWD and MAWBP were downregulated and associated with the differentiation grade in GC tissues. (PMID:26373288)
• Data show that phenazine biosynthesis-like domain-containing protein (PBLD) is aberrantly downregulated in hepatocellular carcinoma (HCC). (PMID:26594798)
• data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circKDM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients (PMID:31406252)
• Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells. (PMID:33121324)
• PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. (PMID:35140333)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	pbld	ENSDARG00000016704
danio_rerio	pbld2	ENSDARG00000026359
mus_musculus	Pbld2	ENSMUSG00000020072
mus_musculus	Pbld1	ENSMUSG00000112129
rattus_norvegicus	Pbld1	ENSRNOG00000000386
rattus_norvegicus	Pbld2	ENSRNOG00000069854
caenorhabditis_elegans		WBGENE00011416
caenorhabditis_elegans		WBGENE00011417
caenorhabditis_elegans		WBGENE00011419
caenorhabditis_elegans		WBGENE00011420
caenorhabditis_elegans		WBGENE00235310

Protein

Protein identifiers

Phenazine biosynthesis-like domain-containing protein — P30039 (reviewed: P30039)

Alternative names: MAWD-binding protein, Unknown protein 32 from 2D-page of liver tissue

All UniProt accessions (4): P30039, A0A024QZK5, A0A0C4DFS0, V9GY00

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a positive regulator of the antiviral immune response by modulating innate immunity and viral replication by enhancing type I interferon (IFN-I) response. PBLD enhances IFN-I signaling via multiple pathways. Promotes IRF3-mediated IFN-I production and apoptosis, thereby inhibiting viral replication. Upregulates IFN-I response by activating the NF-kappaB signaling pathway, potentially through inhibition of TRIM21-mediated degradation of phosphorylated IKKbeta, thereby sustaining NF-kappaB activation to counteract viral infection. Additionally, promotes the p53-USP4-MAVS signaling axis by stabilizing MAVS through USP4-mediated deubiquitination, thereby enhancing the IFN-I response against RNA virus infection. Acts as a tumor suppressor, regulating development of various cancers.

Subunit / interactions. Interacts with STRAP.

Similarity. Belongs to the PhzF family.

Isoforms (2)

UniProt ID	Names	Canonical?
P30039-1	1	yes
P30039-2	2

RefSeq proteins (2): NP_001028255, NP_071412* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003719	Phenazine_PhzF-like	Family

Pfam: PF02567

UniProt features (6 total): sequence variant 3, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30039-F1	95.61	0.93

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 138 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, MODULE_93, GOBP_DIGESTION, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_POSITIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, chr10q21, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, GOBP_CYTOKINE_PRODUCTION, GOBP_MAINTENANCE_OF_GASTROINTESTINAL_EPITHELIUM

GO Biological Process (8): apoptotic process (GO:0006915), maintenance of gastrointestinal epithelium (GO:0030277), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), regulation of type I interferon production (GO:0032479), positive regulation of type I interferon production (GO:0032481), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), antiviral innate immune response (GO:0140374), biosynthetic process (GO:0009058)

GO Molecular Function (5): isomerase activity (GO:0016853), identical protein binding (GO:0042802), molecular_function (GO:0003674), catalytic activity (GO:0003824), protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
type I interferon production	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
epithelial structure maintenance	1
digestive system process	1
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regulation of cytokine production	1
positive regulation of cytokine production	1
regulation of type I interferon production	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
innate immune response	1
defense response to virus	1
metabolic process	1
catalytic activity	1
protein binding	1
molecular_function	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

552 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PBLD	STRAP	Q9Y3F4	981
PBLD	RUFY2	Q8WXA3	538
PBLD	ATOH7	Q8N100	454
PBLD	ZNRD2	O60232	436
PBLD	TMEM50A	O95807	425
PBLD	TMTC2	Q8N394	415
PBLD	MYPN	Q86TC9	391
PBLD	FRMPD2	Q68DX3	386
PBLD	FAM131C	Q96AQ9	384
PBLD	VRK1	Q99986	366
PBLD	ASB7	Q9H672	365
PBLD	RPAP3	Q9H6T3	358
PBLD	RFLNA	Q6ZTI6	356
PBLD	FRMD8	Q9BZ67	353
PBLD	LARP4	Q71RC2	346

IntAct

57 interactions, top by confidence:

A	B	Type	Score
PBLD	EFHC2	psi-mi:“MI:0915”(physical association)	0.780
EFHC2	PBLD	psi-mi:“MI:0915”(physical association)	0.780
PBLD	ZRANB1	psi-mi:“MI:0915”(physical association)	0.760
CCDC184	PBLD	psi-mi:“MI:0915”(physical association)	0.720
PBLD	CCDC184	psi-mi:“MI:0915”(physical association)	0.720
TRIP13	PBLD	psi-mi:“MI:0915”(physical association)	0.670
PBLD	TRIP13	psi-mi:“MI:0915”(physical association)	0.670
PBLD	PBLD	psi-mi:“MI:0915”(physical association)	0.670
PLEKHS1	PBLD	psi-mi:“MI:0915”(physical association)	0.590
TCF4	PBLD	psi-mi:“MI:0915”(physical association)	0.560
LNX1	PBLD	psi-mi:“MI:0915”(physical association)	0.560
PBLD	TCF4	psi-mi:“MI:0915”(physical association)	0.560
PBLD	LNX1	psi-mi:“MI:0915”(physical association)	0.560
PBLD	VAC14	psi-mi:“MI:0915”(physical association)	0.560
AMOT	PBLD	psi-mi:“MI:0915”(physical association)	0.560
PBLD	BEND7	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (38): PBLD (Two-hybrid), PBLD (Two-hybrid), PBLD (Two-hybrid), EFHC2 (Two-hybrid), LNX1 (Two-hybrid), CCDC184 (Two-hybrid), ZRANB1 (Affinity Capture-MS), PBLD (Affinity Capture-MS), PBLD (Affinity Capture-MS), PBLD (Two-hybrid), ZRANB1 (Affinity Capture-MS), PBLD (Affinity Capture-MS), PBLD (Affinity Capture-MS), PBLD (Affinity Capture-MS), PBLD (Two-hybrid)

ESM2 similar proteins: A1CP85, A3QFI1, A6R8Q8, A8X493, B0WSW8, B3MZN7, B3NY19, B4PYH5, B6JVD0, C0NL63, C4JYG6, C5G8R4, C5JKE6, C6HCG7, D0A8W2, D5SQS4, P05165, P07547, P0DTA4, P14882, P30039, P37757, P38765, P58292, P73125, P87241, Q08DA5, Q0D0F3, Q16P87, Q21657, Q2HJF4, Q32LQ3, Q383H9, Q3SX04, Q42777, Q4V7F3, Q5I0C3, Q5RDZ1, Q68EH8, Q68G31

Diamond homologs: O31570, P30039, P37757, P40788, P58292, P58293, Q5RDZ1, Q9A3I3, Q9HY42, Q9KBH7, Q9RUQ2, Q2HJF4, Q68G31, Q8NIL3, Q98KN6, Q9CKV2, Q9CXN7, Q9DCG6, Q9I073, Q9KG32, O69754, Q51520, Q51792, P0A5G8, P38765, P73125, P9WL42, P9WL43, Q9P7P9, Q9KMG3

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2214 predictions. Top by Δscore:

Variant	Effect	Δscore
10:68288925:TCTTA:T	donor_loss	1.0000
10:68288926:CTTA:C	donor_loss	1.0000
10:68288927:TTAC:T	donor_loss	1.0000
10:68288928:TACCT:T	donor_loss	1.0000
10:68288929:A:AC	donor_gain	1.0000
10:68288930:C:CC	donor_gain	1.0000
10:68288930:C:CG	donor_loss	1.0000
10:68289020:C:CC	acceptor_gain	1.0000
10:68296264:A:AC	donor_gain	1.0000
10:68296265:C:CC	donor_gain	1.0000
10:68296268:A:AC	donor_gain	1.0000
10:68296884:A:AC	donor_gain	1.0000
10:68296885:C:CC	donor_gain	1.0000
10:68306759:A:AC	donor_gain	1.0000
10:68306760:C:CC	donor_gain	1.0000
10:68306760:CA:C	donor_gain	1.0000
10:68306904:CTT:C	acceptor_gain	1.0000
10:68306907:C:CC	acceptor_gain	1.0000
10:68306908:T:C	acceptor_gain	1.0000
10:68306908:T:TC	acceptor_gain	1.0000
10:68332215:GG:G	donor_gain	1.0000
10:68332216:GG:G	donor_gain	1.0000
10:68332223:G:GT	donor_gain	1.0000
10:68332226:G:GG	donor_gain	1.0000
10:68332232:GGGG:G	donor_gain	1.0000
10:68332233:GGGG:G	donor_gain	1.0000
10:68288601:C:A	donor_gain	0.9900
10:68288663:T:C	acceptor_gain	0.9900
10:68289016:CAGT:C	acceptor_gain	0.9900
10:68289019:TCT:T	acceptor_loss	0.9900

AlphaMissense

1883 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:68306812:G:C	F11L	0.996
10:68306812:G:T	F11L	0.996
10:68306814:A:G	F11L	0.996
10:68296344:A:G	W69R	0.995
10:68296344:A:T	W69R	0.995
10:68288493:G:C	D227E	0.993
10:68288493:G:T	D227E	0.993
10:68288495:C:G	D227H	0.993
10:68296339:A:C	F70L	0.993
10:68296339:A:T	F70L	0.993
10:68296341:A:G	F70L	0.993
10:68288494:T:C	D227G	0.992
10:68296923:A:C	F49L	0.991
10:68296923:A:T	F49L	0.991
10:68296925:A:G	F49L	0.991
10:68288494:T:G	D227A	0.989
10:68288527:C:G	R216T	0.989
10:68288955:A:T	V163D	0.989
10:68288494:T:A	D227V	0.988
10:68306788:A:C	N19K	0.988
10:68306788:A:T	N19K	0.988
10:68285381:A:G	W241R	0.987
10:68285381:A:T	W241R	0.987
10:68288526:T:A	R216S	0.987
10:68288526:T:G	R216S	0.987
10:68296306:A:C	H81Q	0.987
10:68296306:A:T	H81Q	0.987
10:68306793:C:A	G18W	0.987
10:68296290:C:G	A87P	0.986
10:68296295:G:T	A85D	0.985

dbSNP variants (sampled 300 via entrez): RS1000152563 (10:68316791 T>C), RS1000228517 (10:68297256 G>A), RS1000237599 (10:68285868 A>G,T), RS1000292075 (10:68332632 A>T), RS1000294505 (10:68289632 G>A,C), RS1000327056 (10:68310149 A>G), RS1000377888 (10:68303693 C>G,T), RS1000405323 (10:68322596 C>T), RS1000420993 (10:68326667 T>G), RS1000455859 (10:68296585 C>A,G,T), RS1000515525 (10:68282562 C>A,T), RS1000573550 (10:68287747 TTTG>T), RS1000598362 (10:68296833 C>T), RS1000666591 (10:68289875 C>T), RS1000725840 (10:68332461 A>G)

Disease associations

OMIM: gene MIM:612189 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST000657_5	Optic nerve measurement (disc area)	2.000000e-10
GCST000699_2	Optic disc parameters	3.000000e-35
GCST000700_8	Vertical cup-disc ratio	2.000000e-08
GCST004047_2	Optic nerve measurement (cup-to-disc ratio)	1.000000e-13
GCST009427_2	Optic disc radius	4.000000e-11
GCST009462_11	Optic disc size	3.000000e-209
GCST009462_12	Optic disc size	1.000000e-56
GCST90020028_49	Hip circumference adjusted for BMI	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006939	cup-to-disc ratio measurement
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	8
Aflatoxin B1	affects expression, decreases expression, decreases methylation	3
Hydrogen Peroxide	affects expression, decreases expression	2
Tetrachlorodibenzodioxin	affects expression, decreases expression	2
Cyclosporine	decreases expression	2
sotorasib	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
monomethylarsonous acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
perfluorohexanesulfonic acid	increases expression	1
clothianidin	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	decreases expression	1
Air Pollutants	decreases expression	1
Arsenic	affects methylation	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Estradiol	decreases expression	1
Ethyl Methanesulfonate	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7WM	Ubigene A-549 PBLD KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.